Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2026)

Halozyme Therapeutics (HALO) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $47.5 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $47.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $47.5 million (changed N/A YoY), and the FY2025 annual result was $42.9 million, down 57.25% from the prior year.
• Non-Current Deferred Tax Liability improved to $47.5 million in Q1 2026 per HALO's latest filing, from $42.9 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $100.4 million in Q4 2024 and troughed at $3.3 million in Q2 2022.
• A 4-year average of $32.1 million and a median of $21.3 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 31.24% in 2025 and fell as far as 57.25% in 2025.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $29.0 million in 2022, then soared by 246.36% to $100.4 million in 2024, then tumbled by 57.25% to $42.9 million in 2025, then grew by 10.73% to $47.5 million in 2026.
• Business Quant data shows HALO's Non-Current Deferred Tax Liability at $47.5 million in Q1 2026, $42.9 million in Q4 2025, and $8.2 million in Q3 2025.